These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 25123847)

  • 1. Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection.
    Schmid S; Bryce R; Reeder B; Rana M; Pahwa P; Shoker A; Moser MA
    Ann Transplant; 2014 Aug; 19():403-6. PubMed ID: 25123847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
    Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
    Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients.
    Arreola-Guerra JM; Serrano M; Morales-Buenrostro LE; Vilatobá M; Alberú J
    Ann Transplant; 2016 Feb; 21():105-14. PubMed ID: 26879833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
    Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
    Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.
    Pollock-Barziv SM; Finkelstein Y; Manlhiot C; Dipchand AI; Hebert D; Ng VL; Solomon M; McCrindle BW; Grant D
    Pediatr Transplant; 2010 Dec; 14(8):968-75. PubMed ID: 21040278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very early serum creatinine as a surrogate marker for graft survival beyond 10 years.
    Pascual J; Marcén R; Zamora J; Fernández AM; Burgos FJ; Villafruela JJ; Ortuño J
    J Nephrol; 2009; 22(1):90-8. PubMed ID: 19229823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.
    Staatz C; Taylor P; Tett S
    Nephrol Dial Transplant; 2001 Sep; 16(9):1905-9. PubMed ID: 11522877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2007 Dec; 39(10):3135-41. PubMed ID: 18089339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
    Venkat VL; Nick TG; Wang Y; Bucuvalas JC
    Pediatr Transplant; 2008 Feb; 12(1):67-72. PubMed ID: 18186891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.